Cours Nabriva Therapeutics PLC - ADR Nasdaq
Actions
US62957M1045
Recherche biotechnologique et médicale
CA 2021 | 28,9 M 26,18 M | CA 2022 | 36,94 M 33,46 M | Capitalisation | 5,79 M 5,25 M |
---|---|---|---|---|---|
Résultat net 2021 | -49 M -44,39 M | Résultat net 2022 | -57 M -51,64 M | VE / CA 2021 | -0,2 x |
Trésorerie nette 2021 | 39,64 M 35,91 M | Trésorerie nette 2022 | 7,19 M 6,52 M | VE / CA 2022 | -0,04 x |
PER 2021 |
-0,53
x | PER 2022 |
-0,09
x | Employés | - |
Rendement 2021 * |
-
| Rendement 2022 |
-
| Flottant | 99,05% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
H. Hogan
CEO | Chief Executive Officer | 61 | 07/07/23 |
Dave Maggio
DFI | Director of Finance/CFO | 64 | 30/06/23 |
Steven Gelone
BRD | Director/Board Member | 56 | 23/06/17 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 23/06/17 |
Director/Board Member | 69 | 24/07/18 | |
Stephen Webster
BRD | Director/Board Member | 63 | 01/08/16 |
Varia. 1 janv. | Capi. | |
---|---|---|
+8,96% | 105 Md | |
-1,43% | 104 Md | |
+4,40% | 22,94 Md | |
-12,15% | 22,34 Md | |
-4,36% | 19,25 Md | |
-39,98% | 17,08 Md | |
-10,04% | 16,96 Md | |
+38,61% | 12,63 Md | |
+313,59% | 8,49 Md |